Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.68 |
| ▸ | NT5E | P21589 | 2/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15854472 | 1.00 | GPBAR1 (0.68) | GPBAR1NT5EPRKCD | |
| SCHEMBL15362614 | 1.00 | GPBAR1 (0.68) | GPBAR1NT5EPRKCD | |
| SCHEMBL15362635 | 0.91 | GPBAR1 (0.57) | GPBAR1 | |
| SCHEMBL15848559 | 0.91 | GPBAR1 (0.57) | GPBAR1 | |
| SCHEMBL23284058 | 0.90 | GPBAR1 (0.82) | GPBAR1NT5EPRKCD | |
| SCHEMBL9130783 | 0.89 | GPBAR1 (0.80) | GPBAR1NT5EPRKCD | |
| SCHEMBL13814595 | 0.89 | GPBAR1 (0.80) | GPBAR1NT5EPRKCD | |
| SCHEMBL23284121 | 0.89 | GPBAR1 (0.80) | GPBAR1NT5EPRKCD | |
| SCHEMBL15714058 | 0.88 | GPBAR1 (0.73) | GPBAR1NT5EPRKCD | |
| SCHEMBL3781851 | 0.87 | GPBAR1 (0.84) | GPBAR1PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174570-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2023-06-08 | — | — | US | disclosed |
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174570-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | CYP51A1, CCR5, CYP4A11 | GPBAR1 1643/4885NT5E 2855/4885PRKCD 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.